Diskgen Intervertebral

: The FDA has granted IDCT Fast Track and Regenerative Medicine Advanced Therapy (RMAT) designations, which may accelerate the approval process. Patient Access and Enrollment

While DiskGen represents a leap forward in technology, it is not suitable for every back pain patient. Ideal candidates generally meet the following criteria: diskgen intervertebral

: Unlike palliative treatments that only mask pain, IDCT uses a proprietary population of live Discogenic Cells —progenitor cells derived from donated adult human disc tissue. These cells are injected into the degenerated disc to reduce inflammation and potentially restore disc structure from within. : The FDA has granted IDCT Fast Track

DiskGen represents the shifting paradigm in spinal surgery—from to restoration . For patients suffering from the debilitating effects of degenerative disc disease, these devices offer a glimmer of hope: a future where they can find relief from pain without sacrificing the freedom of movement. These cells are injected into the degenerated disc

Intervertebral disc degeneration (IDD) is a leading cause of chronic low back pain, affecting millions of people worldwide and often serving as a precursor to more severe spinal conditions. While traditional treatments range from physical therapy to invasive surgeries like spinal fusion, a new era of regenerative medicine is emerging. At the forefront of this shift is (often referred to in clinical contexts as IDCT or rebonuputemcel ), a pioneering cell-based therapy developed by DiscGenics . What is DiskGen (IDCT)?